Additional Subscription for 11m Shares
Summary by AI BETAClose X
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
24 September 2025
Renalytix plc
("Renalytix" or the "Company")
Additional Institutional Subscription for 11 million Shares
Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that, further to the Company's announcements dated 22 September 2025 regarding the Placing and Subscription which raised gross proceeds of £5.20 million, the Company has entered into an additional subscription agreement following inbound interest from a new institutional investor (the "Additional Subscription").
Pursuant to the terms of the Additional Subscription Agreement, ABRDN World Healthcare Fund has subscribed for 11,000,000 Subscription Shares at the Issue Price of 9.5 pence per share (the "Additional Subscription Shares") for an aggregate Subscription of £1.045 million ($1.410 million).
The funds raised via the Additional Subscription will further support the Company's commercial distribution efforts, which includes the recently announced collaboration with Tempus AI, Inc. (NASDAQ: TEM).
James McCullough, CEO of Renalytix, commented: "We are particularly pleased with the strong institutional support we have received at this critical time for accelerating growth with our U.S. kidneyintelX.dkd prognostic testing and unique data accumulation program in diabetes and kidney disease."
Admission and Total Voting Rights
Application will be made to the London Stock Exchange for the Additional Subscription Shares to be admitted to trading on the AIM. It is expected that Admission of the Additional Subscription Shares will become effective and that dealings in the Additional Subscription Shares will commence at 8.00 a.m. on Monday 29 September 2025, the same day as the 45,487,903 Second Tranche Placing Shares. This will follow the Admission of the 9,253,679 First Tranche Placing Shares on Friday 26 September 2025. The Retail Offer Shares are also expected to be admitted to trading on AIM on Monday 29 September 2025.
The Additional Subscription Shares when issued, will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.
A further announcement will be made regarding the Company's enlarged issued share capital and Total Voting Rights once the result of the Retail Offer has been confirmed.
Capitalised terms used in this announcement have the meanings given to them in the Company's 'Proposed Fundraise' and 'Result of Fundraise' announcements dated 22 September 2025, unless the context provides otherwise.
For further information, please contact:
|
Renalytix Plc James McCullough, CEO
|
Via Walbrook PR |
|
|
SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker) Jeff Keating / David Hignell (Corporate Finance) Vadim Alexandre (Corporate Broking)
|
Tel: 0203 470 0470
|
|
|
Oberon Capital (Sole Bookrunner and Joint Broker) Mike Seabrook / Nick Lovering / Aimee McCusker
|
Tel: 020 3179 5300
|
|
|
Walbrook PR Limited Paul McManus / Alice Woodings |
Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07407 804 654
|
|
The person responsible for making this Announcement on behalf of the Company is
James McCullogh, Chief Executive Officer.
Forward-Looking Statements
This Announcement includes "forward-looking statements" which includes all statements other than statements of historical fact, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These and other risks are described more fully in the Company's filings with the SEC, including the "Risk Factors" section of its Annual Report on Form 10-K filed with the SEC, and other filings the Company makes with the SEC from time to time. These forward-looking statements speak only as at the date of this Announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies.
No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.
This Announcement does not constitute a recommendation concerning any investor's investment decision with respect to the Fundraise. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this Announcement and publicly available information.
The new Ordinary Shares to be issued pursuant to the Fundraise will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange plc.
The price and value of Ordinary Shares of the Company can go down as well as up. Past performance is not a guide to future performance.
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this Announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 13 minutes ago HGCapital Trust
- 44 minutes ago London Stock Exchange Group
- 1 hour ago Tatton Asset Management
- 2 hours ago Zotefoams
- 3 hours ago Antofagasta